- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Nutrition and Metabolism
Volume 2012 (2012), Article ID 431574, 8 pages
Neonatal SSRI Exposure Programs a Hypermetabolic State in Adult Mice
Department of Pediatrics, Carver College of Medicine, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA
Received 1 December 2011; Revised 3 February 2012; Accepted 5 February 2012
Academic Editor: Barbara Alexander
Copyright © 2012 Gary J. Kummet et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- N. I. Gavin, B. N. Gaynes, K. N. Lohr, S. Meltzer-Brody, G. Gartlehner, and T. Swinson, “Perinatal depression: a systematic review of prevalence and incidence,” Obstetrics & Gynecology, vol. 106, no. 5, pp. 1071–1083, 2005.
- W. O. Cooper, M. E. Willy, S. J. Pont, and W. A. Ray, “Increasing use of antidepressants in pregnancy,” American Journal of Obstetrics & Gynecology, vol. 196, no. 6, pp. 544.e1–544.e5, 2007.
- ACOG Committee on Practice Bulletins—Obstetrics, “Use of psychiatric medications during pregnancy and lactation,” Obstetrics & Gynecology, vol. 111, no. 4, pp. 1001–1020, 2008.
- M. K. Bakker, P. Kölling, P. B. van den Berg, H. E. K. de Walle, and L. T. W. de Jong van den Berg, “Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands,” British Journal of Clinical Pharmacology, vol. 65, no. 4, pp. 600–606, 2008.
- T. F. Oberlander, W. Warburton, S. Misri, J. Aghajanian, and C. Hertzman, “Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data,” Archives of General Psychiatry, vol. 63, no. 8, pp. 898–906, 2006.
- C. L. Wichman, A. Fothergill, K. M. Moore, T. R. Lang, R. H. Heise Jr., and W. J. Watson, “Recent trends in selective serotonin reuptake inhibitor use in pregnancy,” Journal of Clinical Psychopharmacology, vol. 28, no. 6, pp. 714–716, 2008.
- C. D. Chambers, S. Hernandez-Diaz, L. J. van Marter et al., “Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn,” The New England Journal of Medicine, vol. 354, no. 6, pp. 579–587, 2006.
- L. A. Croen, J. K. Grether, C. K. Yoshida, R. Odouli, and V. Hendrick, “Antidepressant use during pregnancy and childhood autism spectrum disorders,” Archives of General Psychiatry, vol. 68, no. 11, pp. 1104–1112, 2011.
- S. Davidson, D. Prokonov, M. Taler et al., “Effect of exposure to selective serotonin reuptake inhibitors. In Utero on fetal growth: potential role for the IGF-I and HPA axes,” Pediatric Research, vol. 65, no. 2, pp. 236–241, 2009.
- R. H. Kelly, J. Russo, V. L. Holt et al., “Psychiatric and substance use disorders as risk factors for low birth weight and preterm delivery,” Obstetrics & Gynecology, vol. 100, no. 2, pp. 297–304, 2002.
- R. Levinson-Castiel, P. Merlob, N. Linder, L. Sirota, and G. Klinger, “Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants,” Archives of Pediatrics and Adolescent Medicine, vol. 160, no. 2, pp. 173–176, 2006.
- T. F. Oberlander, J. A. Gingrich, and M. S. Ansorge, “Sustained neurobehavioral effects of exposure to ssri antidepressants during development: molecular to clinical evidence,” Clinical Pharmacology and Therapeutics, vol. 86, no. 6, pp. 672–677, 2009.
- T. F. Oberlander, R. Grunau, L. Mayes et al., “Hypothalamic-pituitary-adrenal (HPA) axis function in 3-month old infants with prenatal selective serotonin reuptake inhibitor (SSRI) antidepressant exposure,” Early Human Development, vol. 84, no. 10, pp. 689–697, 2008.
- H. J. Romijn, M. A. Hofman, and A. Gramsbergen, “At what age is the developing cerebral cortex of the rat comparable to that of the full-term newborn human baby?” Early Human Development, vol. 26, no. 1, pp. 61–67, 1991.
- D. Maciag, K. L. Simpson, D. Coppinger et al., “Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry,” Neuropsychopharmacology, vol. 31, no. 1, pp. 47–57, 2006.
- R. D. Darling, L. Alzghoul, J. Zhang et al., “Perinatal citalopram exposure selectively increases locus ceruleus circuit function in male rats,” Journal of Neuroscience, vol. 31, no. 46, pp. 16709–16715, 2011.
- K. L. Simpson, K. J. Weaver, E. de Villers-Sidani et al., “Perinatal antidepressant exposure alters cortical network function in rodents,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 45, pp. 18465–18470, 2011.
- N. Donner and R. J. Handa, “Estrogen receptor beta regulates the expression of tryptophan-hydroxylase 2 mRNA within serotonergic neurons of the rat dorsal raphe nuclei,” Neuroscience, vol. 163, no. 2, pp. 705–718, 2009.
- T. Shinozaki, M. Kimura, M. Hosoyamada, and T. Shibasaki, “Fluvoxamine inhibits weight gain and food intake in food restricted hyperphagic wistar rats,” Biological and Pharmaceutical Bulletin, vol. 31, no. 12, pp. 2250–2254, 2008.
- A. Z. Scalco, M. U. P. B. Rondon, I. C. Trombetta et al., “Muscle sympathetic nervous activity in depressed patients before and after treatment with sertraline,” Journal of Hypertension, vol. 27, no. 12, pp. 2429–2436, 2009.
- M. M. Shores, M. Pascualy, N. L. Lewis, D. Flatness, and R. C. Veith, “Short-term sertraline treatment suppresses sympathetic nervous system activity in healthy human subjects,” Psychoneuroendocrinology, vol. 26, no. 4, pp. 433–439, 2001.
- G. E. Erkonen, G. M. Hermann, R. L. Miller et al., “Neonatal leptin administration alters regional brain volumes and blocks neonatal growth restriction-induced behavioral and cardiovascular dysfunction in male mice,” Pediatric Research, vol. 69, no. 5, pp. 406–412, 2011.
- P. A. Matthews, A.-M. Samuelsson, P. Seed et al., “Fostering in mice induces cardiovascular and metabolic dysfunction in adulthood,” Journal of Physiology, vol. 589, no. 16, pp. 3969–3981, 2011.
- M. C. Cheung, P. B. Spalding, J. C. Gutierrez et al., “Body surface area prediction in normal, hypermuscular, and obese mice,” Journal of Surgical Research, vol. 153, no. 2, pp. 326–331, 2009.
- D. Du Bois and E. F. Du Bois, “A formula to estimate the approximate surface area if height and weight be known,” Archives of Internal Medicine, vol. 17, pp. 863–871, 1916.
- V. Hendrick, Z. N. Stowe, L. L. Altshuler, S. Hwang, E. Lee, and D. Haynes, “Placental passage of antidepressant medications,” The American Journal of Psychiatry, vol. 160, no. 5, pp. 993–996, 2003.
- G. M. Hermann, R. L. Miller, G. E. Erkonen et al., “Neonatal catch up growth increases diabetes susceptibility but improves behavioral and cardiovascular outcomes of low birth weight male mice,” Pediatric Research, vol. 66, no. 1, pp. 53–58, 2009.
- M. P. Freeman, P. E. Nolan Jr., M. F. Davis et al., “Pharmacokinetics of sertraline across pregnancy and postpartum,” Journal of Clinical Psychopharmacology, vol. 28, no. 6, pp. 646–653, 2008.
- M. Reis, T. Aamo, O. Spigset, and J. Ahlner, “Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database,” Therapeutic Drug Monitoring, vol. 31, no. 1, pp. 42–56, 2009.
- D. J. Skene, S. E. Timbers, B. Middleton et al., “Mice convert melatonin to 6-sulphatoxymelatonin,” General and Comparative Endocrinology, vol. 147, no. 3, pp. 371–376, 2006.
- J. B. Kornum, R. B. Nielsen, L. Pedersen, P. B. Mortensen, and M. Nørgaard, “Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis,” Clinical Epidemiology, vol. 2, no. 1, pp. 29–36, 2010.
- C. Louik, A. E. Lin, M. M. Werler, S. Hernández-Díaz, and A. A. Mitchell, “First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects,” The New England Journal of Medicine, vol. 356, no. 26, pp. 2675–2683, 2007.
- C. W. Noorlander, F. F. T. Ververs, P. G. J. Nikkels, C. J. A. van Echteld, G. H. A. Visser, and M. P. Smidt, “Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities,” PLoS ONE, vol. 3, no. 7, Article ID e2782, 2008.
- L. H. Pedersen, T. B. Henriksen, M. Vestergaard, J. Olsen, and B. H. Bech, “Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study,” British Medical Journal, vol. 339, Article ID b3569, 2009.
- T. C. B. J. Deiró, R. Manhães-de-Castro, J. E. Cabral-Filho et al., “Sertraline delays the somatic growth and reflex ontogeny in neonate rats,” Physiology and Behavior, vol. 87, no. 2, pp. 338–344, 2006.
- L. M. Tremaine, W. M. Welch, and R. A. Ronfeld, “Metabolism and disposition of the 5-hydroxytryptamine uptake blocker sertraline in the rat and dog,” Drug Metabolism and Disposition, vol. 17, no. 5, pp. 542–550, 1989.
- R. A. Ronfeld, L. M. Tremaine, and K. D. Wilner, “Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers,” Clinical Pharmacokinetics, vol. 32, supplement 1, pp. 22–30, 1997.
- G. Klinger, D. Frankenthal, P. Merlob et al., “Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome,” Journal of Perinatology, vol. 31, no. 9, pp. 615–620, 2011.
- M. Anelli, A. Bizzi, S. Caccia, A. M. Codegoni, C. Fracasso, and S. Garattini, “Anorectic activity of fluoxetine and norfluoxetine in mice, rats and guinea-pigs,” Journal of Pharmacy and Pharmacology, vol. 44, no. 8, pp. 696–698, 1992.
- S. Dryden, H. M. Frankish, Q. Wang, L. Pickavance, and G. Williams, “The serotonergic agent fluoxetine reduces neuropeptide Y levels and neuropeptide Y secretion in the hypothalamus of lean and obese rats,” Neuroscience, vol. 72, no. 2, pp. 557–566, 1996.
- P. D. Gluckman, M. A. Hanson, C. Cooper, and K. L. Thornburg, “Effect of in utero and early-life conditions on adult health and disease,” The New England Journal of Medicine, vol. 359, no. 1, pp. 6–73, 2008.
- P. Zill, A. Büttner, W. Eisenmenger, H. J. Möller, M. Ackenheil, and B. Bondy, “Analysis of tryptophan hydroxylase I and II mRNA expression in the human brain: a post-mortem study,” Journal of Psychiatric Research, vol. 41, no. 1-2, pp. 168–173, 2007.
- N. Perroud, E. Neidhart, B. Petit et al., “Simultaneous analysis of serotonin transporter, tryptophan hydroxylase 1 and 2 gene expression in the ventral prefrontal cortex of suicide victims,” American Journal of Medical Genetics B, vol. 153, no. 4, pp. 909–918, 2010.
- V. B. Singh, K. C. Corley, T. H. Phan, and M. C. Boadle-Biber, “Increases in the activity of tryptophan hydroxylase from rat cortex and midbrain in response to acute or repeated sound stress are blocked by adrenalectomy and restored by dexamethasone treatment,” Brain Research, vol. 516, no. 1, pp. 66–76, 1990.
- S. W. Kim, S. Y. Park, and O. Hwang, “Up-regulation of tryptophan hydroxylase expression and serotonin synthesis by sertraline,” Molecular Pharmacology, vol. 61, no. 4, pp. 778–785, 2002.
- S. A. Sakowski, T. J. Geddes, D. M. Thomas, E. Levi, J. S. Hatfield, and D. M. Kuhn, “Differential tissue distribution of tryptophan hydroxylase isoforms 1 and 2 as revealed with monospecific antibodies,” Brain Research, vol. 1085, no. 1, pp. 11–18, 2006.
- N. Abumaria, R. Rygula, C. Hiemke et al., “Effect of chronic citalopram on serotonin-related and stress-regulated genes in the dorsal raphe nucleus of the rat,” European Neuropsychopharmacology, vol. 17, no. 6-7, pp. 417–429, 2007.
- S. R. Hintz, D. E. Kendrick, B. R. Vohr, W. K. Poole, and R. D. Higgins, “Gender differences in neurodevelopmental outcomes among extremely preterm, extremely-low-birthweight infants,” Acta Paediatrica, vol. 95, no. 10, pp. 1239–1248, 2006.
- E. Zambrano, C. J. Bautista, M. Deás et al., “A low maternal protein diet during pregnancy and lactation has sex- and window of exposure-specific effects on offspring growth and food intake, glucose metabolism and serum leptin in the rat,” Journal of Physiology, vol. 571, no. 1, pp. 221–230, 2006.
- N. B. Ojeda, S. Intapad, T. P. Royals et al., “Hypersensitivity to acute ANG II in female growth-restricted offspring is exacerbated by ovariectomy,” American Journal of Physiology, vol. 301, no. 4, pp. R1199–R1205, 2011.
- K. Nakamura, Y. Sugawara, K. Sawabe et al., “Late developmental stage-specific role of tryptophan hydroxylase 1 in brain serotonin levels,” Journal of Neuroscience, vol. 26, no. 2, pp. 530–534, 2006.
- N. de Pedro, R. M. Martínez-Álvarez, and M. J. Delgado, “Melatonin reduces body weight in goldfish (Carassius auratus): effects on metabolic resources and some feeding regulators,” Journal of Pineal Research, vol. 45, no. 1, pp. 32–39, 2008.
- B. Prunet-Marcassus, M. Desbazeille, A. Bros et al., “Melatonin reduces body weight gain in sprague dawley rats with diet-induced obesity,” Endocrinology, vol. 144, no. 12, pp. 5347–5352, 2003.
- C. F. Reyes-Toso, I. R. Rebagliati, C. R. Ricci et al., “Effect of melatonin treatment on oxygen consumption by rat liver mitochondria,” Amino Acids, vol. 31, no. 3, pp. 299–302, 2006.